Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Clinical trial NCT02890329 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02890329
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Previously Treated Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related Recurrent Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory Myelodysplastic Syndrome Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndrome

Start date: 2017-09-05
Primary completion: 2022-10-24
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.